Table V.
Response to therapy and survival of patients with acute myeloid leukemia
| t-AML N=301 |
t-AML without AHD N= 183 |
t-AML with AHD N= 118 |
P | |
|---|---|---|---|---|
| Type of induction chemotherapy, No. (%) | ||||
| Cytarabine-based | 121 (40) | 89 (49) | 32 (27) | <0.001 |
| Hypomethylating agent-based | 91 (30) | 41 (22) | 50 (42) | |
| Investigational agent | 33 (11) | 17 (9) | 16 (14) | |
| Low intensity chemotherapy | 56 (17) | 36 (20) | 20 (17) | |
| Response, No. (%) | ||||
| CR | 126 (42) | 86 (47) | 40 (34) | 0.047 |
| CRp | 33 (11) | 16 (9) | 17 (14) | |
| PR | 3 (1) | 3 (2) | 0 (0) | |
| HI | 6 (2) | 2 (1) | 4 (3) | |
| No response/death | 133 (44) | 76 (42) | 57 (48) | |
| 1-year RFS, (%) | 52 | 43 | 70 | 0.032 |
| 2-year RFS, (%) | 42 | 34 | 59 | |
| 1-year OS, (%) | 35 | 34 | 35 | 0.525 |
| 2-year OS, (%) | 21 | 20 | 24 | |
| ASCT, No. (%) | 32 (11) | 23 (13) | 9 (8) | 0.175 |
Abbreviations: t-AML, therapy-related acute myeloid leukemia; AHD, antecedent history of myelodysplasia; CR, complete response; CRp, complete response without platelet recovery; HI, hematologic improvement; RFS, relapse-free survival; OS, overall survival; ASCT, allogeneic stem cell transplantation.